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Introduction. Karlsson Linnér et al.1 conducted genome-wide association analyses of general risk 
tolerance (n = 975,353), adventurousness and risky behaviors in the driving, drinking, smoking 
and sexual domains. In separate hold-out cohorts, they analyzed the predictive power of polygenic 
scores derived from the genome-wide association study (GWAS) estimates. Due to data access 
restrictions, it is not possible to release summary statistics for more than 10,000 single nucleotide 
polymorphisms (SNPs). Therefore, researchers with access to the individual-level genotype data 
cannot reproduce the polygenic scores that were used in the paper from publicly available summary 
statistics (https://www.thessgac.org/data). As a partial remedy, we are releasing the polygenic 
scores that were used in the paper’s prediction analyses in the Add Health and UKB-siblings 
cohorts to researchers (but due to the restrictions, we cannot release the underlying SNP-level 
weights themselves). 
Scores for European-ancestry Add Health respondents are available here:  
“KarlssonLinner_et_al_(2019)_PGS_AddHealth.txt” 
 
The Add Health sample is described below. In that sample, Karlsson Linnér et al.1 estimated the 
predictive power of a polygenic score based on summary statistics from the paper’s primary meta-
analysis of general risk tolerance (n = 975,353). If you use these scores, please cite: 
Karlsson Linnér, R. et al. Genome-wide association analyses of risk tolerance and risky behaviors 
in over 1 million individuals identify hundreds of loci and shared genetic influences. Nat. Genet. 
51, 245–257 (2019). 
The purpose of this document is to briefly describe the construction of the scores and the Add 
Health sample. For additional details, readers are referred to the Supplementary Note of Karlsson 
Linnér et al.1, especially Sections 2 (GWAS, Quality Control and Meta-analysis) and 10 
(Predictive Power of General-Risk-Tolerance Polygenic Score). 
Methodology. A polygenic score for an individual is defined as a weighted sum of a person’s 
genotypes at M SNPs, 
 
?̂?𝑆𝑖𝑖 = � 𝑔𝑔𝑖𝑖𝑖𝑖𝛽𝛽𝑖𝑖𝑀𝑀
𝑖𝑖=1
 (1) 
We employed two methods to generate the weights 𝛽𝛽𝑖𝑖. First, we used the software Plink2 to 
produce classical scores. For classical polygenic scores, the estimated additive effect size ?̂?𝛽𝑖𝑖 for 
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SNP j is the GWAS estimate for SNP j. Second, we used the LDpred3 method, a Bayesian method 
that includes all measured SNPs and weights each SNP by (an approximation) of its conditional 
effect, given other SNPs. The theory underlying LDpred is derived assuming the variance-
covariance matrix of the genotype data in the training sample is known and assuming some prior 
effect-size distribution. In practice, the matrix is not known but must be approximated using LD 
patterns from a reference sample. LDpred calculates posterior effect-size distributions for the true 
conditional effect sizes b (i.e., the effect sizes conditional on all other SNPs in a window), and 
each SNP’s weight is set equal to the mean of its (conditional) posterior effect-size distribution. 
Genotype data and imputation for the Add Health individuals. Genotype data from the Illumina 
Omni 1.1 and 2.5 chips were available for 9,975 Add Health5 individuals and 606,673 variants. 
We imputed these genotypes against the Haplotype Reference Consortium (HRC) v1.1 European 
reference panel4 using the Michigan Imputation Server. Prior to imputation, we identified the non-
European individuals by plotting the principal components (PCs) of the covariance matrix of the 
individuals’ genotype data together with the PCs of 1000 Genomes populations6 and visually 
inspecting the plots. We dropped the identified 4,187 non-European individuals from the sample. 
Additionally, we excluded individuals that do not satisfy the following criteria: (i) genotype 
missingness rate is less than 0.05 in all chromosomes, (ii) there is no mismatch between surveyed 
sex and genetic sex, (iii) the individual is not an outlier in terms of heterozygosity/homozygosity, 
and (iv) the individual is not an ancestral outlier. We also dropped SNPs that have a call rate less 
than 0.98, Hardy-Weinberg exact test P-value less than 10-4, or minor allele frequency < 0.01. 
 
Next, we checked the data against the HRC reference panela for consistency of strand, id names, 
positions, alleles, reference/alternative allele assignment, and allele frequency differences using 
version 4.2.5 of the HRC-1000G-check-bim.plb program. The program updates strand, position 
and reference/alternative allele assignment when possible. It removes a SNP if it has any of the 
following properties: (i) A/T or G/C alleles and a minor allele frequency greater than 0.4, (ii) 
alleles that do not match the HRC data, (iii) minor allele frequency discrepancy with the HRC data 
greater than 0.2, (iv) not available in the HRC data. After all checks, 346,754 SNPs remained 
which were taken forward for imputation. Genotype probabilities were imputed for 39,117,084 
variants and 5,690 individuals. To construct the scores for the individuals in our prediction sample, 
we used only the subset of SNPs in the HapMap consortium phase 3 release7 8 and we used best-
guess genotypes. 
Polygenic scores. We provide three types of polygenic scores for risk tolerance based on different 
summary statistics and weight-estimation methods. All three scores were constructed from meta-
analyses that did not contain the Add Health cohort:  
(i) A classical score, calculated using Plink, based on standard GWAS summary statistics 
estimated from a univariate GWAS of general risk tolerance. That score does not take 
into account LD patterns in the GWAS sample. The GWAS summary statistics are from 
a meta-analysis that combines the discovery and replication cohorts in Karlsson Linnér 
et al., which does not include the sample of Add Health (n = 975,353);  
 
a Site list was downloaded from http://www.haplotype-reference-consortium.org/site   
b Script available at http://www.well.ox.ac.uk/~wrayner/tools/HRC-1000G-check-bim.v4.2.5.zi   
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(ii) An LDpred score based on the same GWAS summary statistics as (i) (but estimated 
using LDpred, which accounts for LD patterns in the GWAS sample); and  
(iii) An LDpred score based on the MTAG9 summary statistics for risk tolerance, which 
were obtained from a multivariate analysis of the same GWAS summary statistics of 
risk tolerance as (i) (n = 975,353); adventurousness (n = 557,923); automobile speeding 
propensity (n = 404,291); drinks per week (n = 414,343); ever smoker (n = 518,633); 
number of sexual partners (n = 370,711); and lifetime cannabis use (n = 32,330) (see 
Table 1 below and Supplementary Information Section 10 of Karlsson Linnér et al.1 
for additional details).  
For the two LDpred scores, we adjusted the weights for linkage disequilibrium using the LDpred 
software tool3 and the reference genotype data whose construction is described below. The LD-
adjusted univariate GWAS weights were obtained for SNPs that are available in both the reference 
data and the standard GWAS summary statistics for the phenotype, and that pass the filters 
imposed by LDpred: (i) the variant has a minor allele frequency (MAF) greater than 1% in the 
reference data, (ii) the variant does not have ambiguous nucleotides, (iii) there is no mismatch 
between nucleotides in the summary statistics and reference data, and (iv) there is no high (>0.15) 
MAF discrepancy between summary statistics and validation sample. The LD-adjusted MTAG 
weights were further restricted to SNPs that are available in the GWAS summary statistics for all 
seven phenotypes. The number of SNPs included in the classical score and LDpred GWAS score 
is 1,167,185. The number of SNPs included in the LDpred MTAG score is 1,110,220. The 
posterior effect sizes were calculated assuming a fraction of causal SNPs equal to 0.3 and setting 
the LD window to M/3000, where M is the number of SNPs included in the score. 
We completed the last step of calculating the scores in Plink v1.92, using the Add Health 
individuals’ best-guess genotype data and the LD-adjusted weights described above, for 4,755 Add 
Health individuals. 
Estimation of LD patterns (for the two LDpred scores). We estimated LD patterns using the HRC 
(Haplotype Reference Consortium) Genomes-imputed genotype data (Version 1.1) of Add Health. 
To obtain the LD reference data, we converted the genotype probabilities for 38,898,725 biallelic 
SNPs to hard calls using Plink v1.92. We restricted the set of genetic variants to 1,211,662 
HapMap37 SNPs, because these SNPs are generally well-imputed and provide good coverage of 
the genome in European-ancestry individuals. Next, we estimated a genetic relatedness matrix, 
restricting further to SNPs with minor allele frequency greater than 0.01. We dropped one 
individual from each of the 934 pairs of individuals with a genetic relatedness exceeding 0.02.  
In order to make sure that there are no genetic outliers in the sample that can bias the LD estimates, 
we clustered the remaining 4,756 individuals based on identity-by-state distances in Plink v1.92, 
again restricting to SNPs with minor allele frequency greater than 0.01. Plink reports a Z-score for 
each individual’s identity-by-state distance to his/her closest neighbor. We examined these Z-
scores and marked an individual as genetic outlier if his/her Z-score was smaller than -5. One such 
individual was identified who was then dropped from the sample. The process was repeated, 
confirming that no individual with a Z-score less than -5 remained in the sample. In the final data 
set, there were 4,755 individuals and 1,211,662 SNPs. 
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Table 1. Phenotype measures  
Phenotype Measure Uses 
General  
risk tolerance 
 
Meta-analysis of UK Biobank, 23andMe and 10 smaller 
cohorts:  
UK Biobank10: Would you describe yourself as someone 
who takes risks? [1] Yes, [2] No 
23andMe11: In general, people often face risks when making 
financial, career, or other life decisions. Overall, do you feel 
comfortable or uncomfortable taking risks? [1] Very 
comfortable, [2] Somewhat comfortable, [3] Neither 
comfortable nor uncomfortable, [4] Somewhat 
uncomfortable, [5] Very uncomfortable 
Detailed measures of general risk tolerance for the 10 
smaller cohorts are in the Supplementary Table 4 of Karlsson 
Linnér et al.1 
GWAS of general 
risk tolerance  
+ 
MTAG analysis 
with general risk 
tolerance as the 
primary phenotype 
Adventurousness  If forced to choose, would you consider yourself to be more 
cautious or more adventurous? [1] Very cautious, [2] 
Somewhat cautious, [3] Neither, [4] Somewhat adventurous, 
[5] Very adventurous 
MTAG analysis 
with general risk 
tolerance as the 
primary phenotype 
Automobile 
speeding 
propensity 
How often do you drive faster than the speed limit on the 
motorway? [1] Never/rarely, [2] Sometimes, [3] Often, [4] 
Most of the time, [5] Do not drive on the motorway 
We first dropped all participants who reported not driving on 
the motorway, and then we normalized our categorical 
variable for males and females separately. 
MTAG analysis 
with general risk 
tolerance as the 
primary phenotype 
Drinks per week 
 
Our drinks per week measure is constructed from responses to 
a sequence of questions in the UK Biobank10.  
First, respondents were asked how often they drink alcohol, 
and response options include [1] Daily or almost daily, [2] 
Three or four times per week, [3] Once or twice per week, [4] 
One to three times per month, [5] Special occasions only, and 
[6] Never 
Respondents who reported drinking once per week or more 
were asked how many glasses of various types of alcoholic 
beverages they consume per week. We used the sum of all 
alcoholic drinks per week as our drinks per week phenotype 
for these respondents.  
Respondents who reported drinking less than once per week 
MTAG analysis 
with general risk 
tolerance as the 
primary phenotype 
 5 
(one to three times per month or on special occasions only) 
were asked how many glasses of various types of alcoholic 
beverages they consume per month. For these respondents, we 
added the total number of drinks per month and divided by 4 
to arrive at an approximated number of drinks per week.  
Respondents who reported never drinking were coded as 0. 
 
Ever smoker Meta-analysis of the following two studies:  
UK Biobank10: we coded ever-tobacco smoker status as 1 if a 
respondent reported that they were a current or previous 
smoker and 0 if they reported never smoking or only smoking 
once or twice. We coded cigarettes per day as 0 if ever-
smoking status was also 0; otherwise, we used the maximum 
number of reported past or current cigarettes (or pipes/cigars) 
consumed per day, normalized separately for males and 
females. 
Tobacco, Alcohol and Genetics (TAG) Consortium12: A 
published meta-analysis of 16 cohorts. 
MTAG analysis 
with general risk 
tolerance as the 
primary phenotype 
Number of  
sexual partners 
About how many sexual partners have you had in your 
lifetime? 
If respondents reported more than 99 lifetime sexual partners, 
they were asked to confirm their responses. We assigned a 
value of 0 to participants who reported having never had sex, 
and we again normalized this measure separately for males 
and females. 
MTAG analysis 
with general risk 
tolerance as the 
primary phenotype 
Lifetime  
cannabis use 
GWAS summary statistics from a published study.13 MTAG analysis 
with general risk 
tolerance as the 
primary phenotype 
 
A note on the MTAG-based polygenic score. MTAG9 is a method that uses GWAS summary 
statistics for a primary phenotype and for one or more secondary phenotypes to produce an updated 
set of summary statistics for the primary phenotype which, under certain assumptions, will be more 
precisely estimated than the input GWAS summary statistics. 
There are costs and benefits to using an MTAG-based polygenic score. For instance, in all cases, 
MTAG-based polygenic scores will be more predictive of their corresponding phenotype in 
expectation. In some cases, however, MTAG can have a high false discovery rate (see 
 6 
Supplementary Note section 1.4 of Turley et al.9), which may lead to spurious correlations between 
the MTAG-based polygenic score and other phenotypes. 
We therefore offer the following recommendations. If in a regression, the dependent variable and 
the polygenic score correspond to the same phenotype, we recommend using the MTAG-based 
score. If the dependent variable and the polygenic score correspond to different phenotypes, but 
the coefficient of interest in the regression is not the coefficient associated with the polygenic score 
(e.g., if the polygenic score is only being used as a control variable in an experimental setting), 
then we also recommend using the MTAG-based polygenic score. Care should be taken when 
interpreting the coefficient of an MTAG-based polygenic score in this setting, however, since any 
observed association may be driven through channels involving the secondary phenotypes. This is 
especially true when the maxFDR is large (see Turley et al.9, Supplementary Note section 1.4). If 
researchers are interested in the coefficient on the polygenic score, they should either use GWAS-
based scores, or justify why such channels would lead to negligible bias in their particular case.  
Principal components. It is important to take a number of steps to minimize the risk that an 
observed association between the outcome of interest and the polygenic score is due to 
unaccounted-for population stratification. A score is stratified if its distribution varies across 
members of different ancestry groups. Failure to control for differences in ancestry can severely 
bias estimates of effect sizes, since members of different groups may vary in the outcome of 
interest for environmental reasons14. To reduce such concerns, we recommend controlling for the 
top 10 ancestry-specific principal components (PCs) of the covariance matrix of the individuals’ 
genotypic data15, which are included in “KarlssonLinner_et_al_(2019)_PGS_AddHealth.txt”.  
Variables. Table 2 provides a description of the variables included in 
“KarlssonLinner_et_al_(2019)_PGS_AddHealth.txt”. 
 
Table 2. Description of variables 
Variable Description 
aid Individual identifier 
FID 
PGS_RISK_PLINK_GWAS 
Family identifier  
Polygenic score for general risk tolerance, obtained using classic PLINK 
method and standard GWAS results 
PGS_RISK_LDPRED_GWAS Polygenic score for general risk tolerance, obtained using LDpred 
method and standard GWAS results 
PGS_RISK_LDPRED_MTAG Polygenic score for general risk tolerance, obtained using LDpred 
method and results from multivariate analysis of adventurousness, 
automobile speeding propensity, drinks per week, ever smoker, number 
of sexual partners, and lifetime cannabis use 
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PC1 - PC10 Top 10 principal components (PCs) of the covariance matrix of the 
individuals’ genotypic data 
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